このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

CareDx マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

John Hanna

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	2.1yrs
取締役会の平均在任期間	9.3yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

John Hanna (44 yo)

less than a year

在職期間

Mr. John Walter Hanna, Jr. is President, CEO & Director of CareDx, Inc since April 15, 2024. He served as General Manager of Endocrinology, Breast Cancer and Lymphoma at Veracyte, Inc. since January 1, 202...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Abhishek Jain	CFO & Principal Accounting Officer	2.1yrs	US$3.09m	0.059% $ 408.9k
Peter Maag	Executive Director	2.6yrs	US$354.93k	0.47% $ 3.3m
Alexander Johnson	President of Patient & Testing Services	4.1yrs	US$3.10m	0.11% $ 753.8k
John Hanna	President	less than a year	データなし	データなし
Marica Grskovic	Chief Operating Officer	2.4yrs	データなし	データなし
Robert Woodward	Chief Scientific Officer	less than a year	データなし	データなし
GS Jha	Senior VP	1.4yrs	データなし	データなし
Jeffrey Novack	General Counsel & Secretary	less than a year	データなし	0.24% $ 1.6m
Stacey Follon	Senior VP & Head of Human Resources	1.4yrs	データなし	データなし
Kashif Rathore	Chief of Patient & Digital Solutions	no data	データなし	データなし
Hal Gibson	Senior Vice President of Strategic Planning	2.3yrs	データなし	データなし
Marco Scheller	Senior Vice President of Clinical Operations	2.4yrs	データなし	データなし

2.1yrs

平均在職期間

47yo

平均年齢

経験豊富な経営陣: 1K9の経営陣は経験豊富であると考えられます ( 2.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Peter Maag	Executive Director	11.6yrs	US$354.93k	0.47% $ 3.3m
John Hanna	President	less than a year	データなし	データなし
Fred Cohen	Independent Director	21.4yrs	US$355.87k	0.22% $ 1.5m
Michael Goldberg	Independent Chairman	12.6yrs	US$456.03k	0.17% $ 1.2m
Christine Cournoyer	Independent Director	4.8yrs	US$384.45k	0.047% $ 322.6k
William Hagstrom	Independent Director	9.3yrs	US$360.87k	0.047% $ 325.6k
Jeffrey Bluestone	Member of Advisory Board	no data	データなし	データなし
Mary Crow	Member of Advisory Board	no data	データなし	データなし
Robert Tibshirani	Member of Advisory Board	no data	データなし	データなし
George Bickerstaff	Independent Director	10.2yrs	US$368.74k	0.17% $ 1.1m
R. Riggsbee	Independent Director	less than a year	データなし	データなし
Arthur Torres	Independent Director	2.8yrs	US$353.74k	0.013% $ 92.3k

9.3yrs

平均在職期間

67.5yo

平均年齢

経験豊富なボード: 1K9の取締役会は経験豊富であると考えられます ( 9.3年の平均在任期間)。

CareDx マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

CareDx, Inc, Annual General Meeting, Jun 13, 2024

CareDx, Inc Appoints John W. Hanna as Chief Executive Officer

CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors

CareDx, Inc Announces Resignation of Reginald Seeto as Chief Executive Officer

CareDx, Inc Announces Executive Changes

CareDx, Inc Announces Resignation of Ralph Snyderman as Director, Effective from December 31, 2022

Recent updates

CareDx, Inc Announces New Data to Be Presented At the 2024 American Transplant Congress

Study Shows CareDx, Inc.’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.44 loss in 1Q 2023)

CareDx, Inc, Annual General Meeting, Jun 13, 2024

CareDx, Inc Appoints John W. Hanna as Chief Executive Officer

CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors

CareDx, Inc Provides Revenue Guidance for the Full Year of 2024

Full year 2023 earnings released: US$3.54 loss per share (vs US$1.44 loss in FY 2022)

CareDx, Inc to Report Q4, 2023 Results on Feb 28, 2024

Jury Rules in Favor of Natera, Inc in Patent Infringement Lawsuit Against CareDx, Inc

CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

CareDx, Inc to Report Q3, 2023 Results on Nov 08, 2023

CareDx, Inc Announces Resignation of Reginald Seeto as Chief Executive Officer

CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents

CareDx, Inc Announces Executive Changes

SEC Concludes Investigation as to CareDx and Does Not Intend to Recommend an Enforcement Action

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.46 loss per share (vs US$0.41 loss in 2Q 2022)

CareDx, Inc. Provides Revenue Guidance for the Full Year 2023

CareDx, Inc to Report Q2, 2023 Results on Aug 08, 2023

CareDx, Inc. Announces Medicare Coverage for HeartCare

CareDx, Inc (NasdaqGM:CDNA) acquired MediGO, Inc.

CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring

New major risk - Share price stability

First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.37 loss in 1Q 2022)

CareDx, Inc to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$1.44 loss per share (vs US$0.59 loss in FY 2021)

CareDx, Inc. Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions At the 2023 Tandem Meetings

CareDx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

CareDx, Inc (NasdaqGM:CDNA) announces an Equity Buyback for $50 million worth of its shares.

CareDx, Inc Announces the Results of A New Study Published in Transplantation Direct

CareDx, Inc Announces Resignation of Ralph Snyderman as Director, Effective from December 31, 2022

Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.23 loss in 3Q 2021)

Caredx, Inc., Revises Revenue Guidance for the Full Year 2022

Independent Longitudinal Study Finds Caredx’S Allosure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

CareDx, Inc to Report Q3, 2022 Results on Nov 03, 2022

Caredx, Inc Announces Transplant Patients Experience Less Pain and Fewer Adverse Events with Caredx Non-Invasive Testing Solutions

CareDx, Inc Announces Executive Changes

CareDx, Inc Announces Resignation of Sasha King as Chief Marketing Officer

Independent Director recently sold €60k worth of stock

CareDx, Inc Revises Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.037 loss in 2Q 2021)

CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care

CareDx, Inc to Report Q2, 2022 Results on Aug 04, 2022

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Caredx, Inc

Saxena White P.A. Files New Securities Fraud Class Action Against CareDx, Inc

Natera Drops One of Their Two Patents Originally Asserted Against CareDx, Inc

Independent Director recently sold €113k worth of stock

CareDx, Inc Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.37 loss per share (vs US$0.013 loss in 1Q 2021)

CareDx, Inc, Annual General Meeting, Jun 15, 2022

Caredx Demonstrates Potential of Alloheme and Allocell for Allogeneic Cell Transplant and Therapy Monitoring

Independent Director recently sold €871k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

CareDx, Inc Provides Revenue Guidance for the Year 2022

CareDx, Inc to Report Q4, 2021 Results on Feb 24, 2022

Forecast to breakeven in 2024

CareDx, Inc. Announces the Publication of Results from A Large, Multicenter Prospective Study

Caredx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Forecast to breakeven in 2024

Caredx, Inc Announces the Results of Study Led by the National Institutes of Health

CareDx, Inc Successfully Completes CLIA Validation of Allomap Kidney in Preparation for Commercial Launch

CareDx, Inc (NasdaqGM:CDNA) acquired The Transplant Pharmacy.

CareDx, Inc Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes

Chief Financial Officer recently bought €189k worth of stock

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.057 loss in 3Q 2020)

CareDx, Inc. to Present Six Abstracts on AlloSeq cfDNA and launch of AlloSeq cfDNA Research Service at European Society of Organ Transplantation (ESOT) 2021 conference

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.15 loss in 2Q 2020)

マネジメント基準チェック /24